AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00741832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conical Positive Expiratory Pressure Device (C-PEP)
Description: Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.~The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.~Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device.
Study NCT00741832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control breathing
Description: Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
Study NCT01834586 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anesthetic Topical Adhesive Synera
Description: For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week
Study NCT00265720 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Written materials only
Study NCT00265720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced out of pocket expense
Description: Reimbursed up to $500 out of pocket expense for CRC screening
Study NCT00265720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: one on one education
Description: one on one education with a health educator
Study NCT00265720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group education
Description: Education in a small group
Study NCT01390441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-8808
Description: MK-8808 500 mg/m\^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
Study NCT01390441 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MK-8808
Description: MK-8808 500 mg/m\^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
Study NCT01390441 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera® (rituximab)
Description: MabThera® 500 mg/m\^2 or 1000 mg administered by IV on Day 1 and Day 15
Study NCT01390441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
Study NCT01390441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
Study NCT01390441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituxan® (rituximab)
Description: Rituxan® 1000 mg administered by IV on Day 1 and Day 15
Study NCT01390441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Study NCT01390441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Study NCT01390441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Study NCT01390441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Study NCT01390441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Study NCT01390441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Study NCT01380977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Crime group intervention
Description: A group intervention for 16 1.5 hr sessions held twice a week
Study NCT01380977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of Crime group intervention
Description: A group intervention for 16 1.5 hr sessions held twice a week
Study NCT00440245 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: salbutamol
Description: 200 micrograms salbutamol from MDI
Study NCT03446638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-approved drug or combination of drugs
Description: Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).
Study NCT03446638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLAG induction
Description: Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days. 5 mg/kg per day of granulocyte colony stimulating factor (G-CSF) may be given subcutaneously beginning on Day 1 of each treatment until absolute granulocyte count > 500/ microliter for 3 days.
Study NCT03446638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7 + 3 induction
Description: Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.
Study NCT03446638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose cytarabine
Description: Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.
Study NCT03446638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive care alone
Description: Patients will receive one or more of the following: blood product transfusions, antibiotics, granulocyte colony-stimulating factor (G-CSF), erythropoietic stimulating factors, and iron chelation.
Study NCT00497341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefuroxime
Description: cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm
Study NCT00497341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
Study NCT01962194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, Activa PC+S, which has therapy equivalent to Activa PC, and has a new sensing programmer.
Study NCT01031004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon B
Description: contact lens
Study NCT01031004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens
Study NCT05393687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: progressive eccentric exercise with elastic band
Study NCT03996122 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: 3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)
Study NCT03446638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computational biology simulations software
Description: Genetic testing results for each patient randomized to this arm will be used by a computational biology simulations software program to generate a personalized map of dysregulated metabolic pathways contributing to the patient's disease. This map will then be used to digitally screen for potentially therapeutic FDA-approved drugs or drug combinations to target the dysregulated metabolic pathways.
Study NCT00285376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilazodone
Description: titration to 40mg tablets qd for 8 weeks
Study NCT00285376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vilazodone
Description: titration to 40mg tablets qd for 8 weeks
Study NCT04353206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
Description: Subjects to receive single or double plasma units infused on day 0 and potentially days 3 and 6.
Study NCT02833961 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic resonance imaging
Study NCT02833961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Study NCT03980197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active surveillance and preemptive isolation
Description: Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
Study NCT03980197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
Study NCT02722811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
Study NCT02722811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education, exercise and diet guidance
Description: Health education, exercise and diet guidance in patient; treatment: 8 weeks
Study NCT02722811 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health education, exercise and diet guidance
Description: Health education, exercise and diet guidance in patient; treatment: 8 weeks
Study NCT02625246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hMSCs
Description: intravenous infusion of bone marrow-derived allogeneic stem cells
Study NCT01580683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
Study NCT01580683 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Identical Placebo
Description: Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
Study NCT00460668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: 2 or 3 times a week during 8 weeks
Study NCT02659098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 2476 3.0 x 10^5 cells
Description: Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
Study NCT02659098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subretinal Delivery System
Description: Participants will receive CNTO 2476 by using the Delivery System.
Study NCT04776902 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey
Description: Patients will fill a questionary with 8 questions.
Study NCT01398098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phosphate
Description: 32 tablets
Study NCT04346810 — intervention group
Intervention type: OTHER
Intervention: Patient management suffering of coronavirus infection
Description: Welle-being and stress of the caregivers
Study NCT01667549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of Diet and Flavor Experience
Description: Groups differ in the timing and duration of exposure to flavored food experience.
Study NCT00909532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150-mg tablets given orally q12h for up to 48 weeks
Study NCT00909532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet given orally q12h for up to 48 weeks
Study NCT01130168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, capsule taken orally once daily during 4 weeks of treatment
Study NCT01130168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Amlodipine
Description: Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
Study NCT01130168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: ISMN ER
Description: ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
Study NCT03276390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hispanic Kidney Transplant Program (HKTP)
Description: The HKTP entails culturally targeted education in Spanish about transplantation, outreach to dialysis patients by bicultural health care providers.
Study NCT02637102 — intervention group
Intervention type: OTHER
Intervention: Not applicable - observational study
Study NCT04642547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib and Gefitinib
Description: First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight > 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight > 60Kg), oral.
Study NCT03513068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Oxygen Concentrator (POC)
Description: COPD patients prescribed with LTOT will be randomized to receive a portable oxygen concentrator (POC)
Study NCT02461862 — intervention group
Intervention type: BEHAVIORAL
Intervention: Application of the Visual Analog Scale of pain
Description: Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
Study NCT02461862 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of blood pressure
Description: Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
Study NCT02461862 — intervention group
Intervention type: PROCEDURE
Intervention: Evaluation of radial pulse
Description: Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
Study NCT01209598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 200mg
Description: Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
Study NCT01209598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food.
Study NCT03993275 — intervention group
Intervention type: DEVICE
Intervention: MindMotion GO
Description: Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.
Study NCT01224522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visionaire
Description: Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.
Study NCT01224522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical technique
Description: Implantation of Genesis II Total Knee system by means of standard surgical technique.
Study NCT04553588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disposal pouch
Description: Medication Disposal Pouch
Study NCT02335905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline Fosamil
Description: IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
Study NCT04592796 — intervention group
Intervention type: DEVICE
Intervention: Xiaomi MiBand2
Description: Recording of sleep and activity data to study their association with age.
Study NCT04592796 — intervention group
Intervention type: OTHER
Intervention: Socio-demographic questionnaire
Description: Self-made questionnaire to be administered at the beginning of the study with the following personal data: age, gender, marital status, residential environment, mobility aids, educational level, occupation, retirement type, socioeconomic status, medical records, treatment.
Study NCT04592796 — intervention group
Intervention type: OTHER
Intervention: EuroQol-5D-5L
Description: Quality of life questionnaire to be administered at the beginning and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
Study NCT04592796 — intervention group
Intervention type: OTHER
Intervention: Mini mental State Examination
Description: Questionnaire to be administered at the beginning and completion of the study that measures cognitive impairment.
Study NCT03206268 — intervention group
Intervention type: DEVICE
Intervention: SD-OCT and SLP using GDx variable corneal compensation
Description: RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
Study NCT00430742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taranabant
Description: Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
Study NCT00430742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo capsule once daily. Treatment for 52 weeks.
Study NCT01791413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: depot medroxyprogesterone acetate
Description: DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
Study NCT01932268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
Study NCT02188537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Nelfinavir 2x 2500 mg p.o. days 1 - 14
Study NCT02188537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11
Study NCT02188537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
Study NCT00513747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV over 4 hours
Study NCT00513747 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Given IV over 4 hours
Study NCT04592796 — intervention group
Intervention type: OTHER
Intervention: Tinetti Scale
Description: Physical test to be administered at the beginning and completion of the study that measures gait and balance of the participants.
Study NCT04592796 — intervention group
Intervention type: OTHER
Intervention: Barthel Index
Description: Questionnaire to be administered at the beginning and completion that evaluates the level of independence in basic activities of life.
Study NCT04592796 — intervention group
Intervention type: OTHER
Intervention: Pittsburgh Sleep Quality Assessment (PSQI)
Description: Questionnaire to be administered whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning and completion of the study.
Study NCT02295332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral placebo capsules to RG7625, according to treatment schedule
Study NCT00513747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV over 30 minutes
Study NCT00513747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine phosphate
Description: Given IV over 30 minutes
Study NCT02757820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Classic
Description: Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
Study NCT02295332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7625
Description: oral administration, capsules, single ascending dose according to treatment schedule